DIADEMA PARTNERS LP

Position in CRVS — Corvus Pharmaceuticals, Inc.

CIK 2026172 MORRISTOWN, NJ

Back to CRVS Full portfolio

Position in CRVS

as of Jun 30, 2026 · filed Aug 14, 2026 Compact

Position Value

$4,404,476

+$822,892 QoQ

Shares Held

294,811

+20.4% QoQ

Ownership

0.350%

of shares outstanding

% of Portfolio

1.66%

of 13F equity value

Holder Rank

#38

of 172 holders

Holding Since

Sep 2025

4 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Common Shares in CRVS Over Time

Shares Held

Position Value (USD)

Derivatives in CRVS

reported options exposure · as of Jun 30, 2026

CallValue

$1,992,996

CallShares

133,400

PutValue

PutShares

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

DIADEMA PARTNERS LP holds $217,374,297 across 66 Biotechnology names. CRVS ranks #11 (2.0% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	RVMD	Revolution Medicines, Inc.	139,218	$26,072,747
2	ABVX	Abivax S.A.	163,644	$21,807,199
3	COGT	Cogent Biosciences, Inc.	493,664	$19,104,796
4	BMRN	Biomarin Pharmaceutical Inc	312,846	$17,901,048
5	VKTX	Viking Therapeutics, Inc.	441,808	$17,234,930
6	EWTX	Edgewise Therapeutics, Inc.	272,214	$11,060,054
7	KOD	Kodiak Sciences Inc.	218,117	$8,497,838
8	IMCR	Immunocore Holdings plc	254,863	$8,091,900

All Filings in CRVS

Export CSV

6 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$4,404,476	294,811	+20.4%	Shares	Sole	2026-08-14
2026-06-30	$1,992,996	133,400	+25.5%	Call	Sole	2026-08-14
2026-03-31	$1,555,169	106,300	—	Call	Sole	2026-05-15
2026-03-31	$3,581,584	244,811	—	Shares	Sole	2026-05-15
2025-12-31	$408,870	53,100	+6.2%	Put	Sole	2026-02-17
2025-09-30	$368,500	50,000	—	Put	Sole	2025-11-14
No filing history on record for this holder in this stock.